Prognostic implication of gene mutations on overall survival in the adult acute myeloid leukemia patients receiving or not receiving allogeneic hematopoietic stem cell transplantations

Leukemia Research

Volumn 38, Issue 11, 2014, Pages 1278-1284

  Chou, Sheng Chieh ^a   Tang, Jih Luh ^a   Hou, Hsin An ^a   Chou, Wen Chien ^a   Hu, Fu Chang ^a,b   Chen, Chien Yuan ^a   Yao, Ming ^a   Ko, Bor Sheng ^a   Huang, Shang Yi ^a   Tsay, Woei ^a   Chen, Yao Chang ^a   Tien, Hwei Fang ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Acute myeloid leukemia; Allogeneic hematopoietic stem cell transplantation; Gene mutations

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; CD135 ANTIGEN; CYTARABINE; GUANINE NUCLEOTIDE BINDING PROTEIN; IDARUBICIN; LACTATE DEHYDROGENASE; MITOXANTRONE; MIXED LINEAGE LEUKEMIA PROTEIN; N RAS PROTEIN; NUCLEOPHOSMIN; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DONOR; DRUG MEGADOSE; FAMILY; FEMALE; GENE MUTATION; HEMATOPOIETIC STEM CELL; HUMAN; INDUCTION CHEMOTHERAPY; KARYOTYPE; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREVALENCE; RECURRENCE FREE SURVIVAL; REMISSION; RETROSPECTIVE STUDY; SIBLING; ALLOTRANSPLANTATION; CASE CONTROL STUDY; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA, MYELOID, ACUTE; MUTATION; PROGNOSIS; SURVIVAL;

CASE-CONTROL STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MUTATION; PROGNOSIS; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84910038046     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.08.012     Document Type: Article

References (34)

1. Lowenberg B. Acute myeloid leukemia: the challenge of capturing disease variety. Hematology Am Soc Hematol Educ Program 2008, 1-11.
2. Bacher U., Haferlach C., Schnittger S., Kern W., Kroeger N., Zander A.R., et al. Interactive diagnostics in the indication to allogeneic SCT in AML. Bone Marrow Transplant 2009, 43:745-756.
3. McCormack E., Bruserud O., Gjertsen B.T. Review: genetic models of acute myeloid leukaemia. Oncogene 2008, 27:3765-3779.
4. Mrozek K., Marcucci G., Paschka P., Whitman S.P., Bloomfield C.D. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification. Blood 2007, 109:431-448.
5. Renneville A., Roumier C., Biggio V., Nibourel O., Boissel N., Fenaux P., et al. Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia 2008, 22:915-931.
6. Zaidi S.Z., Owaidah T., Al Sharif F., Ahmed S.Y., Chaudhri N., Aljurf M. The challenge of risk stratification in acute myeloid leukemia with normal karyotype. Hematol Oncol Stem Cell Ther 2008, 1:141-158.
7. Marcucci G., Mrozek K., Bloomfield C.D. Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics. Curr Opin Hematol 2005, 12:68-75.
8. Nimer S.D. Is it important to decipher the heterogeneity of normal karyotype AML. Best Pract Res Clin Haematol 2008, 21:43-52.
9. Koreth J., Schlenk R., Kopecky K.J., Honda S., Sierra J., Djulbegovic B.J., et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009, 301:2349-2361.
10. Gupta V., Tallman M.S., Weisdorf D.J. Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. Blood 2011, 117:2307-2318.
11. Schlenk R.F., Dohner K., Krauter J., Frohling S., Corbacioglu A., Bullinger L., et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008, 358:1909-1918.
12. Brunet S., Labopin M., Esteve J., Cornelissen J., Socie G., Iori A.P., et al. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol 2012, 30:735-741.
13. Tang J.L., Hou H.A., Chen C.Y., Liu C.Y., Chou W.C., Tseng M.H., et al. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood 2009, 114:5352-5361.
14. Gaidzik V.I., Bullinger L., Schlenk R.F., Zimmermann A.S., Rock J., Paschka P., et al. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol 2011, 29:1364-1372.
15. Cheson B.D., Bennett J.M., Kopecky K.J., Buchner T., Willman C.L., Estey E.H., et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003, 21:4642-4649.
16. Hou H.A., Kuo Y.Y., Liu C.Y., Chou W.C., Lee M.C., Chen C.Y., et al. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood 2012, 119:559-568.
17. Hou H.A., Lin C.C., Chou W.C., Liu C.Y., Chen C.Y., Tang J.L., et al. Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia. Leukemia 2014, 28:50-58.
18. Tien H.F., Wang C.H., Lin M.T., Lee F.Y., Liu M.C., Chuang S.M., et al. Correlation of cytogenetic results with immunophenotype, genotype, clinical features, and ras mutation in acute myeloid leukemia. A study of 235 Chinese patients in Taiwan. Cancer Genet Cytogenet 1995, 84:60-68.
19. Grimwade D., Hills R.K., Moorman A.V., Walker H., Chatters S., Goldstone A.H., et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010, 116:354-365.
20. Falini B., Mecucci C., Tiacci E., Alcalay M., Rosati R., Pasqualucci L., et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005, 352:254-266.
21. Shih L.Y., Huang C.F., Wu J.H., Lin T.L., Dunn P., Wang P.N., et al. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood 2002, 100:2387-2392.
22. Chou W.C., Tang J.L., Lin L.I., Yao M., Tsay W., Chen C.Y., et al. Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution. Cancer Res 2006, 66:3310-3316.
23. Lin L.I., Chen C.Y., Lin D.T., Tsay W., Tang J.L., Yeh Y.C., et al. Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res 2005, 11:1372-1379.
24. Shih L.Y., Liang D.C., Huang C.F., Chang Y.T., Lai C.L., Lin T.H., et al. Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples. Leukemia 2008, 22:303-307.
25. Shiah H.S., Kuo Y.Y., Tang J.L., Huang S.Y., Yao M., Tsay W., et al. Clinical and biological implications of partial tandem duplication of the MLL gene in acute myeloid leukemia without chromosomal abnormalities at 11q23. Leukemia 2002, 16:196-202.
26. Hou H.A., Huang T.C., Lin L.I., Liu C.Y., Chen C.Y., Chou W.C., et al. WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. Blood 2010, 115:5222-5231.
27. Ferrant A., Labopin M., Frassoni F., Prentice H.G., Cahn J.Y., Blaise D., et al. Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood 1997, 90:2931-2938.
28. Tallman M.S., Dewald G.W., Gandham S., Logan B.R., Keating A., Lazarus H.M., et al. Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission. Blood 2007, 110:409-417.
29. Gale R.E., Hills R., Kottaridis P.D., Srirangan S., Wheatley K., Burnett A.K., et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood 2005, 106:3658-3665.
30. Bornhauser M., Illmer T., Schaich M., Soucek S., Ehninger G., Thiede C. Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML. Blood 2007, 109:2264-2265. author reply 5.
31. Green C.L., Koo K.K., Hills R.K., Burnett A.K., Linch D.C., Gale R.E. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol 2010, 28:2739-2747.
32. Hou H.A., Lin L.I., Chen C.Y., Tien H.F. Reply to 'Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favorable prognosis'. Br J Cancer 2009, 101:738-740.
33. Armistead P.M., de Lima M., Pierce S., Qiao W., Wang X., Thall P.F., et al. Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia. Biol Blood Marrow Transplant 2009, 15:1431-1438.
34. Walter R.B., Buckley S.A., Pagel J.M., Wood B.L., Storer B.E., Sandmaier B.M., et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood 2013, 122:1813-1821.